1 February 2016 - Sun Pharma's subsidiary received final approval for imatinib mesylate from FDA in December 2015. Being a first-to-file product, it was granted 180 days of marketing exclusivity.

For more details, go to: http://www.prnewswire.com/news-releases/sun-pharma-launches-imatinib-mesylate-in-usa-300212705.html